Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct descriptionProduct information

Special populations

7 evidence topics · 10 sources

Hepatic impairment: single-dose pharmacokinetic study design

“This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.” (opens the source at this quote in a new tab)

“This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.” (opens the source at this quote in a new tab)

“The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio.” (opens the source at this quote in a new tab)

“Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.” (opens the source at this quote in a new tab)

“Has a score on the Child-Pugh scale at screening visit and confirmed at check-in as follows:” (opens the source at this quote in a new tab)

“Mild: ≥5 and ≤6 [Category A]; or” (opens the source at this quote in a new tab)

“Moderate: ≥7 and ≤9 [Category B]; or” (opens the source at this quote in a new tab)

“Severe: ≥10 and ≤15 [Category C].” (opens the source at this quote in a new tab)

Ovarian toxicity in premenopausal women